Hims stock plummeted Monday after Novo Nordisk ended their collaboration over concerns about Hims' compounded semaglutide.

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

Hims & Hers Health stock plunged after Novo Nordisk (NYSE: NVO) cut ties over concerns about its handling of Wegovy ...

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass ...

Danish drugmaker Novo Nordisk A/S said on Monday it is terminating a recently formed obesity-drug partnership with Hims & ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Shares of Hims & Hers Health plummeted in premarket trading Monday after Novo Nordisk terminated its partnership with the ...